TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18163485
Drug: Atacicept (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (70 mg, 210 mg, or 630 mg single doses; 3 doses of 70 mg, 3 doses of 210 mg, or 7 doses of 420 mg repeated doses)
Study: 10805610
Drug: Cocaethylene (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaethylene (0.25 or 0.5 mg/kg)
Study: 22076422
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Group S)
Study: 11336163
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (both diets combined)
Study: 11336163
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (per-protocol analysis)
Study: 3653859
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (radiotherapy and chemotherapy)
Study: 29973265
Drug: Acupuncture treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatments for 4 weeks
Study: 31593273
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of sprifermin administered every 12 months (n=110)
Study: 31593273
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg of sprifermin administered every 6 months (n=111)
Study: 31593273
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg of sprifermin administered every 12 months (n=110)
Study: 31593273
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of sprifermin (both dosing schedules)
Study: 31593273
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg of sprifermin (both dosing schedules)
Study: 19729375
Drug: Standard-dose lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose lopinavir/ritonavir
Study: 19729375
Drug: Low-dose lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose lopinavir/ritonavir
Study: 16566424
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (twice daily 500 mg)
Study: 16566424
Drug: Oral lactobacilli
Normalized name: lactobacillic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lactobacilli (twice daily a capsule with > 10^9 colony-forming units of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Study: 16566424
Drug: Standardised antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised antibiotic therapy (once daily 480 mg trimethoprim-sulfamethoxazole)
Study: 16566424
Drug: Standardised antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised antibiotic therapy
Study: 8973673
Drug: 10.8-mg goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8-mg goserelin acetate depot
Study: 8973673
Drug: 3.6-mg goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6-mg goserelin acetate depot
Study: 6363220
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg daily: 50 mg before breakfast and before evening meal)
Study: 6363220
Drug: Cimetidine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1000 mg daily: 200 mg with breakfast, lunch, and evening meal, and 400 mg at bedtime)
Study: 29734180
Drug: Ranibizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (monthly regimen)
Study: 22217510
Drug: Conventional-dose 17β-estradiol/norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose 17β-estradiol/norethisterone acetate (NETA)
Study: 22217510
Drug: Low-dose 17β-estradiol/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose 17β-estradiol/NETA
Study: 20171140
Drug: Enalapril (EN)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (EN) 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks
Study: 8362431
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no warfarin)
Study: 7572323
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (500 mg/day)
Study: 7572323
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean calcium intake = 376 mg/day)
Study: 7403330
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of dextrose and water with different magnesium, calcium, and potassium solutions
Study: 31765657
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg testosterone gel
Study: 7767193
Drug: Self medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self medication programme
Study: 387230
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with L-PAM
Study: 25185456
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (nifedipine 5 mg once daily and beraprost 20 mg three times daily)
Study: 27922194
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg)
Study: 28482385
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (250 mg/d) orally
Study: 28482385
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotic therapy and conventional treatment)
Study: 21949219
Drug: Carbohydrate counting
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate counting applied to meal A (75 g carbohydrate)
Study: 18035730
Drug: Meropenem (1.5-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1.5-3 g daily)
Study: 18035730
Drug: Standard antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibacterial therapy (betalactams, fluoroquinolones, aminoglycosides, metronidazole)
Study: 8233251
Drug: 40-minute dosing
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-minute dosing protocol (incremental dose 1.5 mU/minute until 7 mU/minute, then 1.5 or 3.0 mU/minute)
Study: 8233251
Drug: 15-minute dosing
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minute dosing protocol
Study: 8233251
Drug: 40-minute dosing
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-minute dosing protocol
Study: 3630857
Drug: Zinc picolinate
Normalized name: Zinc picolinate
DrugBank: Zinc picolinate (DB11175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc picolinate (50 mg elemental zinc per day)
Study: 3630857
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (50 mg elemental zinc per day)
Study: 3630857
Drug: Zinc citrate
Normalized name: Zinc Citrate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc citrate (50 mg elemental zinc per day)
Study: 27806024
Drug: Cisplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (30 mg/m²) and 500,000 U IL-2 for 3 days
Study: 18855271
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of trandolapril and verapamil (FDTV) 2/180 mg once a day
Study: 18855271
Drug: Trandolapril (T)
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril (T) 2 mg once a day
Study: 15889944
Drug: Phenytoin 100
Normalized name: phenytoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 100 mg, increased to 3 times daily (maximum 400 mg/day)
Study: 15889944
Drug: Fluoxetine 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 7 mg, increased to 20 mg/day (3 times daily)
Study: 8607241
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 67.2 Gy
Study: 8607241
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of 75.6 Gy
Study: 31023381
Drug: Motherfit group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motherfit group therapy
Study: 28138164
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with bupivacaine 0.25% (0.50 ml/kg)
Study: 28138164
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (100 mcg/kg)
Study: 28138164
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block with bupivacaine 0.25% (1 mg/kg)
Study: 3088636
Drug: Binedaline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binedaline (100 mg)
Study: 25973434
Drug: Bromocriptine, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine, 2.5 mg oral, twice a day for 14 days after delivery
Study: 23172272
Drug: Allogeneic mesenchymal
Normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic mesenchymal stem cells (MSCs) - 100 × 10⁶ cells/infusion, 4 monthly infusions
Study: 7648682
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 to 50 mg)
Study: 7648682
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg)
Study: 27901214
Drug: Fluoxetine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine therapy (n=91)
Study: 27901214
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (n=91)
Study: 17803715
Drug: 600 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 micrograms oral misoprostol
Study: 30691507
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus PCI
Study: 27746061
Drug: Riociguat 0.5
Normalized name: riociguat 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 0.5 mg (up-titrated to a maximum dose of 2.5 mg TID over 10 weeks)
Study: 10598427
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion (MI group)
Study: 1936477
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Glibenclamide added to Metformin)
Study: 1936477
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Metformin added to Glibenclamide)
Study: 6757152
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mepindolol daily
Study: 29540872
Drug: Conservative exercise
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative exercise therapy with Maitland thoracic manipulation
Study: 18167405
Drug: Testosterone undecenoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecenoate 80 mg twice daily for 6 months
Study: 20044683
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg)
Study: 10633486
Drug: Oral amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amphetamine (30 mg)
Study: 1394754
Drug: Rocuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.25 mg.kg‐1
Study: 1394754
Drug: Rocuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.5 mg.kg‐1
Study: 3915885
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg, 30 mg, 40 mg)
Study: 3915885
Drug: Piroxicam (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (equivalent once-daily dosage)
Study: 12834650
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of professional sessions attended during treatment
Study: 12834650
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of GA meetings attended during treatment
Study: 1958856
Drug: Beta-carotene 30
Normalized name: beta-carotene 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day
Study: 31252655
Drug: Caffeine 3
Normalized name: caffeine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3 mg/kg/b.m. (CAF‐3)
Study: 31252655
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg/kg/b.m. (CAF‐6)
Study: 31252655
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg/kg/b.m. (CAF‐9)
Study: 27007392
Drug: Control (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4 g olive oil)
Study: 10378852
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (0.5 to 1 microg/kg/min)
Study: 8710426
Drug: Dexfenfluramine treatment
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine treatment with a low calorie diet
Study: 8710426
Drug: Dexfenfluramine treatment
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine treatment
Study: 2039811
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg bumetanide
Study: 7014105
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg xipamide
Study: 23842536
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (1 mg/kg)
Study: 29525821
Drug: Atorvastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (2 loading doses of 80 mg before and 24 hours after PCI)
Study: 30640985
Drug: Xingfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingfeng Capsule (XFC), 3 pills each time, three times per day for 3 months
Study: 22258265
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (100,000 IU cholecalciferol given every 2 months) and calcium (1 g/d)
Study: 20073463
Drug: Berry group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berry group (160 g/day of bilberries, lingonberries, black currants, and chokeberries)
Study: 16226521
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of 4 mg triamcinolone acetonide (TA)
Study: 16226521
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 4 mg TA followed by MLG
Study: 12107236
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg, orally, three times daily)
Study: 11772142
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg/day or 10 mg twice daily
Study: 12421488
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg/day
Study: 11772142
Drug: Rabeprazole plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole plus clarithromycin and amoxicillin
Study: 7735957
Drug: Comparison with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with complete murine monoclonal anti-TNF alpha-antibody
Study: 26551066
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (Viscoseal) 10 mL intra-articularly
Study: 26551066
Drug: Bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 10 mL intra-articularly
Study: 17200358
Drug: Epirubicin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 100 mg/m² and Cyclophosphamide 600 mg/m² (EC) every 10 to 11 days for four cycles followed by Paclitaxel 175 mg/m² every 10 to 11 days for four cycles with filgrastim support (300 microg s.c. daily) from day 2 to 24 hours before the next treatment
Study: 6281293
Drug: MK 421
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK 421 (20 mg orally, twice daily)
Study: 31362715
Drug: Six-month ART
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-month ART refill in Intervention ACs, meeting twice annually.
Study: 30594153
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (perioperative arm): 2 cycles nab‐paclitaxel (125 mg/m2)/gemcitabine (1000 mg/m2, d1, 8 and 15 of a 28 day‐cycle) followed by tumor surgery followed by 4 cycles nab‐paclitaxel/gemcitabine
Study: 24518280
Drug: LYM-X-SORB™ (LXS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYM-X-SORB™ (LXS) dietary supplements
Study: 24518280
Drug: Placebo dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dietary supplements
Study: 22997994
Drug: Extensive antiarrhythmic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive antiarrhythmic drugs (AADs) therapy (class Ic and III AADs)
Study: 22997994
Drug: One AAD
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One AAD therapy (class Ic or III AADs alone)
Study: 20678685
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (new generic losartan potassium 50-mg tablet)
Study: 20678685
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (branded losartan potassium 50-mg tablet)
Study: 17127027
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation
Study: 10758775
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation
Study: 394267
Drug: Caerulein (ceruletide)
Normalized name: Passiflora caerulea fruit extract
DrugBank: Ceruletide (DB00403)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caerulein (ceruletide) 0.3 mcg/kg intravenously every 4 hours
Study: 31296289
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban
Study: 30462220
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban
Study: 25222386
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus CABG (610 patients)
Study: 25222386
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (602 patients)
Study: 11957164
Drug: Methylprednisolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (15 mg/kg intravenously 1 hour before surgery and 0.3 mg/kg intravenously every 6 hours for 4 doses)
Study: 10410529
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for pancreatic endocrine tumors
Study: 7586430
Drug: Glyceryl trinitrate-verapamil
Normalized name: glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate-verapamil (GV) solution
Study: 7586430
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (untreated)
Study: 7389482
Drug: Taurolin (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolin (new chemotherapeutic agent)
Study: 7017311
Drug: Conventional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotic therapy
Study: 26337448
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of red wine grape pomace flour (WGPF) per day
Study: 23295262
Drug: Intanza 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intanza 15 μg intradermal vaccine
Study: 23295262
Drug: Inflexal V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inflexal V virosomal adjuvanted intramuscular vaccine
Study: 19366849
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) with glycemia target of 80-110 mg/dl
Study: 19366849
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (CIT) with glycemia target above 215 mg/dl
Study: 16357619
Drug: Nadolol plus
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol plus isosorbide mononitrate (medication group)
Study: 16357619
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (sclerotherapy or ligation) (control group)
Study: 8129382
Drug: Hyperthermia combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia combined with irradiation and chemotherapy (HCR)
Study: 8129382
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy (CR)
Study: 8129382
Drug: Hyperthermia combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia combined with irradiation and chemotherapy (HCR) with cisplatin
Study: 8129382
Drug: Multi-drug combined
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug combined treatment from other institutes
Study: 2656902
Drug: Felodipine extended
Normalized name: Felodipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended release (10 mg)
Study: 26595963
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with yellow turpentine bathtubs and bronchodilators inhalations (atrovent inhalations).
Study: 26595963
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with yellow turpentine bathtubs alone.
Study: 26595963
Drug: Therapeutic physical
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic physical exercises and symptomatic medications (control group).
Study: 23887469
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Control group, n=17)